Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice

Vaccine

Volumn 33, Issue 3, 2015, Pages 417-421

  Vance, David J ^a   Rong, Yinghui ^a   Brey, Robert N ^b   Mantis, Nicholas J ^a,c  

^a WADSWORTH CENTER   (United States)

^b Soligenix Inc   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antigen; Biodefense; Toxin; Vaccine

Indexed keywords

ANTHRAX TOXIN; DNI VACCINE; NEUTRALIZING ANTIBODY; RICIN; RIVAX VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; ANTHRAX VACCINE; ANTITOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; RIVAX; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SUBUNIT; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTHRAX; BAGG ALBINO MOUSE; BLOOD; IMMUNOLOGY; INTOXICATION; PREVENTION AND CONTROL; SURVIVAL;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; FEMALE; MICE, INBRED BALB C; POISONING; RICIN; SURVIVAL ANALYSIS; VACCINES; VACCINES, COMBINED; VACCINES, SUBUNIT;

EID: 84921983089     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.036     Document Type: Article

References (34)

1. Audi J., Belson M., Patel M., Schier J., Osterloh J. Ricin poisoning: a comprehensive review. JAMA 2005, 294:2342-2351.
2. Wolfe D.N., Florence W., Bryant P. Current biodefense vaccine programs and challenges. Hum Vaccines Immunother 2013, 2013.
3. Mantis N.J. Ricin Toxin. Manual of security sensitive microbes and toxins 2014, 1024. CRC Press. D. Liu (Ed.).
4. Reisler R.B., Smith L.A. The need for continued development of ricin countermeasures. Adv Prev Med 2012, 2012:149737.
5. Smallshaw J.E., Vitetta E.S. Ricin vaccine development. Curr Top Microbiol Immunol 2012, 357:259-272.
6. Mantis N.J., Morici L.A., Roy C.J. Mucosal vaccines for biodefense. Curr Top Microbiol Immunol 2011.
7. Neal L.M., McCarthy E.A., Morris C.R., Mantis N.J. Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA. Vaccine 2011, 29:681-689.
8. Smallshaw J.E., Richardson J.A., Vitetta E.S. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 2007, 25:7459-7469.
9. Vitetta E.S., Smallshaw J.E., Coleman E., Jafri H., Foster C., Munford R., et al. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A 2006, 103:2268-2273.
10. Vitetta E.S., Smallshaw J.E., Schindler J. A small phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine (RiVax). Clin Vaccine Immunol 2012.
11. O'Hara J.M., Brey R.N., Mantis N.J. Comparative efficacy in mice of two lead candidate ricin toxin A subunit (RTA) vaccine. Clin Vaccine Immunol 2013, 20:789-794. (in press).
12. Liu S., Moayeri M., Leppla S.H. Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol 2014, 22:317-325.
13. Friedlander A.M., Little S.F. Advances in the development of next-generation anthrax vaccines. Vaccine 2009, 27(Suppl. 4):D28-D32.
14. Yan M., Roehrl M.H., Basar E., Wang J.Y. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Vaccine 2008, 26:947-955.
15. Iyer V., Hu L., Schante C.E., Vance D., Chadwick C., Jain N.K., et al. Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine. Hum Vaccines Immunother 2013, 9:2362-2370.
16. Peek L.J., Brey R.N., Middaugh C.R. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J Pharm Sci 2007, 96:44-60.
17. Neal L.M., O'Hara J., Brey R.N., Mantis N.J. A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun 2010, 78:552-561.
18. Kelly-Cirino C.D., Mantis N.J. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun 2009, 77:4859-4867.
19. Moayeri M., Wiggins J.F., Leppla S.H. Anthrax protective antigen cleavage and clearance from the blood of mice and rats. Infect Immun 2007, 75:5175-5184.
20. Batista F.D., Harwood N.E. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 2009, 9:15-27.
21. Denoel P.A., Goldblatt D., de Vleeschauwer I., Jacquet J.M., Pichichero M.E., Poolman J.T. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007, 14:1362-1369.
22. Eskola J., Olander R.M., Hovi T., Litmanen L., Peltola S., Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996, 348:1688-1692.
23. Reisler R.B., Gibbs P.H., Danner D.K., Boudreau E.F. Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: eastern equine and western equine encephalitis. Vaccine 2012, 30:7271-7277.
24. Compton J.R., Legler P.M., Clingan B.V., Olson M.A., Millard C.B. Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen. Proteins 2011, 79:1048-1060.
25. D'Souza A.J., Mar K.D., Huang J., Majumdar S., Ford B.M., Dyas B., et al. Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine. J Pharm Sci 2013, 102:454-461.
26. Verma A., McNichol B., Dominguez-Castillo R.I., Amador-Molina J.C., Arciniega J.L., Reiter K., et al. Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen. Infect Immun 2013, 81:278-284.
27. Froude J.W., Thullier P., Pelat T. Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) 2011, 3:1433-1452.
28. Mechaly A., Levy H., Epstein E., Rosenfeld R., Marcus H., Ben-Arie E., et al. A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion. J Biol Chem 2012, 287:32665-32673.
29. O'Hara J.M., Yermakova A., Mantis N.J. Immunity to ricin: fundamental insights into toxin-antibody interactions. Curr Top Microbiol Immunol 2012, 357:209-241.
30. O'Hara J.M., Mantis N.J. Neutralizing monoclonal antibodies against ricin's enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro. J Immunol Methods 2013, 395:71-78.
31. Song K., Mize R.R., Marrero L., Corti M., Kirk J.M., Pincus S.H. Antibody to ricin a chain hinders intracellular routing of toxin and protects cells even after toxin has been internalized. PLoS ONE 2013, 8:e62417.
32. O'Hara J.M., Kasten-Jolly J.C., Reynolds C.E., Mantis N.J. Localization of non-linear neutralizing B cell epitopes on ricin toxin's enzymatic subunit (RTA). Immunol Lett 2014, 158:7-13.
33. Dormitzer P.R., Grandi G., Rappuoli R. Structural vaccinology starts to deliver. Nat Rev Microbiol 2012, 10:807-813.
34. Rudolph M.J., Vance D.J., Cheung J., Franklin M.C., Burshteyn F., Cassidy M.S., et al. Crystal structures of ricin toxin's enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies. J Mol Biol 2014, 426:3057-3068.